The OJC Episode 25: IASLC World Conference on Lung Cancer Part 1

Pinterest LinkedIn Tumblr +

First of two Special Episodes dedicated to IASLC World Conference on Lung Cancer

This week we have incredible analysis and some very unique interviews on the IASLC World Conference on Lung Cancer.

We open this first episode with the marvellous musical stylings of Mayhemtom, an International Rockstar by night, who happens to moonlight as a Medical Oncologist by day… Welcome Tom John! He chats with Eva Segelov and Craig Underhill about Keynote 598 and DESTINY.

We also have the wonderful Bishal Gyawali talking us through what he doesn’t adore about ADAURA. Nick Pavlakis introduces us to the newly formed TOGA group and we wrap up with an update from Christian Rolfo on ctDNA in lung.

In Part 2, you’ll hear from Tim Clay, Ben Solomon, Anna Nowak and Gilberto Lopes so look out for Episode 26.

Thanks to everyone who participated and thanks to all our listeners, we hope you enjoy today’s entertaining and informative episode.

About The Oncology Journal Club:

We have taken an old concept and updated it with a new format. In each episode a team of expert contributors will review topical journal papers and interview special guests who are leaders in their fields to help keep you informed of the latest developments on the go.

With The Oncology Podcast – and The Oncology Journal Club in particular – we are aiming to deliver oncology news differently,” Rachael Babin, Editor-in-Chief, Oncology News.

The Oncology Journal Club is hosted by Professor Eva Segelov, from Monash University. Eva is joined by Dr Craig Underhill from Albury-Wodonga and Professor Hans Prenen from Antwerp, Belgium. We hope you enjoy listening and find this a valuable and entertaining resource.

This Week’s Abstracts:

  1. Boyer, M. PS01.09 – Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS ≥50%: KEYNOTE-598. Access online here.
  2. Smit, E.F. MA11.03 – Trastuzumab Deruxtecan in HER2-Mutated Metastatic Non-Small Cell Lung Cancer (NSCLC): Interim Results of DESTINY-Lung01. Access online here.
  3. West H, Gyawali B. Why Not Adore ADAURA?—The Trial We Need vs the Trial We Got. JAMA Oncol. Published online February 04, 2021. doi:10.1001/jamaoncol.2020.6752. Access online here.
  4. Gyawali, B. et al. Cancer groundshot: going global before going to the moon. The Lancet Oncology, Volume 19, Issue 3, 288 – 290. Access online here.
  5. Peled, N. P87.01 – Higher Dose Alectinib for Advanced RET+ NSCLC: Results from the RET+ Cohort of the Blood First Assay Screening Trial (BFAST). Access online here.
  6. Mezquita, L. P84.01 – The ARIA Study: Activity of Next-Generation ALK TKIs Based on ALK Resistance Mutations Detected by Liquid Biopsy in ALK Positive NSCLC Patients. Access online here.
  7. Chorostowska-Wynimko, J. P35.05: The Monitoring of Mutated EGFR Levels in Liquid Biopsy from Patients on EGFR-TKIs – Early Detection of NSCLC Progression. Access online here.
  8. Gedvilaitė, V. P02.24: Liquid Biopsy Mutation Profiling in Non-Small Cell Lung Cancer. Access online here.
  9. Zhuang, W. FP04.03: Dynamic Liquid Biopsy for Selecting Advanced NSCLC Patients for
    Primary Tumor Resection After Targeted Therapy. Access online here.

View the entire WLCL Program in pdf here.

This Week’s Team:

Professor Eva Segelov

Eva Segelov

Professor Eva Segelov is a Medical Oncologist and is Director of Oncology at Monash University and Monash Health, Melbourne, Victoria, previously Senior Medical Oncologist at St Vincent’s Hospital, St Vincent’s Private Hospital and St Vincent’s Clinic and Associate Professor of Medicine, University of New South Wales.

Eva has an interest in academic clinical trials in GI and breast cancer and has been a member of the AGITG since 2003. She has clinical trials expertise, links with national and international trials groups, and extensive experience with adult medical education.


Dr Craig Underhill

Craig Underhill

Dr Craig Underhill completed his Bachelor of Medicine and Surgery in 1987 at Melbourne University. He completed medical oncology training in Melbourne and worked as the Senior Clinical Research Registrar at Guy’s Hospital, London.

In 1998 arrived in Albury-Wodonga and established a medical oncology practice and clinical trials unit which has developed expertise and infrastructure to ensure the initiation of high quality trials. The research Unit lead by Dr Underhill has twice been awarded NSW Premier’s Award for Innovation in Cancer Clinical Trials, the inaugural award in 2009 and then again in 2012.

Dr Underhill chaired a working party that was instrumental in securing $65 million in federal funding for The Albury Wodonga Regional Cancer Centre which opened in September 2016.

Dr Underhill is the VCCC Regional Oncology Lead and advocates for the increased access to clinical trials for regional Victorians and leads the VCCC teletrials program.

Professor Hans Prenen

Hans Prenen

Professor Hans Prenen is a medical oncologist and head of the phase 1 – early clinical trials unit at the Antwerp University Hospital in Belgium. He is a member of several scientific organisations, published many scientific oncology papers in prestigious journals and is regularly invited for lectures at national and international meetings.  His interests are clinical trials and translational research with a focus on digestive oncology.




Tom John

Mayhemtom aka Associate Professor Tom John
Dr Tom John is a Medical Oncologist and Translational Researcher at the Peter MacCallum Cancer Centre in Melbourne. In his day job, he is recognised both nationally and internationally as an expert in cancers of the thoracic cavity, which includes lung cancers, thymus cancers and mesothelioma. He also has an interest in genetics and cancers that may run in some families. His twitter handle is: @TommyJohn00

His alter-ego Mayhemtom is a musician. He currently has a single out ‘Reach Out’ – you can listen to it via your preferred music streaming app here: Mayhemtom is on Twitter too: @mayhemtomi

Associate Professor Bishal Gyawali

Bishal Gyawali

Dr Gyawali is a medical oncologist with work experience in various low- and high- income countries. He graduated medical school in Nepal with seven gold medals and received his PhD from Nagoya University, Japan as a MEXT scholar. He then practiced as a medical oncologist at Civil Service Hospital, Kathmandu, Nepal. He currently works as a medical oncologist and scientist in the Division of Cancer Care and Epidemiology at the Queen’s University Cancer Research Institute in Kingston, Ontario, Canada, where he is also an Assistant Professor of Public Health Sciences.

He also serves as a medical consultant for the not-for-profit Anticancer Fund, Belgium, and as editorial board member for the Journal of Global Oncology and ecancer. His clinical and research interests include cancer policy, global oncology, evidence-based oncology, financial toxicities of cancer treatment, clinical trial methods, and supportive care. Dr. Gyawali is an advocate of the “cancer groundshot,”  a term he coined to imply that research investment should be made on known high-value interventions in cancer care that are affordable and easy to implement globally. Dr. Gyawali is active in the oncology and clinical research communities on Twitter: @oncology_bg

Professor Nick Pavlakis

Nick Pavlakis

Professor Nick Pavlakis is Senior Staff Specialist in the Department of Medical Oncology at Royal North Shore Hospital and conjoint Professor in the Faculty of Medicine University of Sydney. He is current Board Chair of the new Thoracic Oncology Group of Australasia (TOGA), member of the Upper GI Working Party of the Australasian Gastrointestinal Trials Group (AGITG) and is centre lead of the RNSH NET service. He has extensive experience in clinical research leadership in national and international clinical trials in lung cancer, mesothelioma and GI cancers with several current and ongoing collaborative group trials in lung cancer, gastric cancer and NETs. As co-chair of the Bill Walsh Translational Research Laboratories he is involved in translational research in in lung cancer, pancreas and gastric cancers.  Putting evidence into practice he has with experience in systematic reviews and clinical practice guideline development.

Visit the TOGA website or find them on Twitter: @TOGAANZ

Professor Christian Rolfo

Christian Rolfo

Christian Rolfo, MD, PhD, MBA, Dr.hc. is professor in the Division of Hematology-Oncology at University of Maryland School of Medicine and the Director of the Thoracic Medical Oncology and the Early Clinical Trials at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC). He specialises in thoracic oncology, drug development and translational oncology.

Dr. Rolfo actively works on drug development and resistance in lung cancer and mesothelioma treatment. His focus of research are liquid biopsies (exosomes and ctDNA) and molecular profiling, he is involved in druggable biomarkers research and immunotherapy in thoracic cancer.

Dr. Rolfo is the Deputy Chair of the Educational Committee of the International Association for the Study of Lung Cancer (IASLC) and Vice President of The International Society of Liquid Biopsy (ISLB). His Twitter handle is: @ChristianRolfo

Rachael Babin

Rachael Babin

Rachael Babin is Editor-in-Chief of The Oncology Newsletter and Publisher of For regular oncology updates for healthcare professionals, please subscribe to The Oncology Newsletter and follow us on Twitter: @OncologyNewsAus

With thanks to Eva Segelov, Craig Underhill, Hans Prenen, Tom John, Bishal Gyawali, Nick Pavlakis, Christian Rolfo and Graham Knowles.


About Author

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.